semaglutide vs tirzepatide cardiology
Semaglutide's Cardiovascular Edge Isn't What You Think
Semaglutide’s 2 mg dose shows a modest 0.8% absolute reduction in major cardiovascular events compared with standard-dose tirzepatide, but the benefit hinges on dose, patient risk and adherence. Novo Nordisk released the data after a real-world comparison that mixed dose escalation with drug switching, leaving clinicians to parse